Bimekizumab in hidradenitis suppurativa: a valid and effective emerging treatment

Clin Exp Dermatol. 2023 Oct 25;48(11):1272-1274. doi: 10.1093/ced/llad229.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Treatment Outcome

Substances

  • bimekizumab
  • Antibodies, Monoclonal, Humanized